Klinická studie lurbinectedinu v monoterapii nebo v kombinaci s irinotekanem versus topotekanem nebo irinotekanem u pacientů s relapsem malobuněčného karcinomu plic (LAGOON)
Randomizovaná, multicentrická, otevřená studie fáze III lurbinectedinu s jedním činidlem nebo lurbinectedinem v kombinaci s irinotekanem versus výběr zkoušejícího (topotekan nebo irinotekan) u pacientů s recidivou malobuněčného karcinomu plic (studie LAGOON)
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
Approximately 705 Adult SCLC patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2 who have failed one prior platinum-containing line with CTFI ≥ 30 days and controlled asymptomatic and pretreated Central Nervous System metastases will be enrolled and assigned to each treatment arm.
Central randomization will be implemented; patients will be assigned to each treatment arm at a 1:1:1 ratio.
An Independent Data Monitoring Committee (IDMC) will oversee the conduct of the study. The IDMC should have access to unblinded efficacy and safety data throughout the trial to enable timely and informed judgments about risks and benefits.
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
-
Frenchs Forest, Austrálie, NSW 2086
- Northern Beaches Hospital
-
Gosford, Austrálie, 2250
- Gosford Hospital GH - Central Coast Cancer Centre
-
Heidelberg, Austrálie, VIC 3084
- Austin Hospital- Medical Oncology Unit
-
Murdoch, Austrálie, WA 6150
- St John of God Murdoch Hospital
-
Wollongong, Austrálie, NSW 2500
- Cancer Care Wollongong
-
-
New South Wales
-
Camperdown, New South Wales, Austrálie, 2050
- The Chris Obrien Lifehouse
-
-
Victoria
-
Ballarat Central, Victoria, Austrálie, 3350
- BRICC - Ballarat Health Services
-
Box Hill, Victoria, Austrálie, 3128
- Box Hill Hospital Eastern Health Clinical School
-
-
-
-
-
Brasschaat, Belgie, 2930
- Algemeen Ziekenhuis AZ Klina - Borstkliniek
-
Charleroi, Belgie, 6000
- Grand Hopital de Charleroi GHdC - Hopital Saint Joseph
-
Liège, Belgie, 4000
- CHR de la Citadelle
-
Liège, Belgie, 4000
- Centre Hospitalier Chretien CHC - MontLegia
-
Liège, Belgie, 4000
- CHU Liege
-
Mechelen, Belgie, 2800
- Az Sint Maarten Mechelen
-
Mons, Belgie, 7000
- Centre Hospitalier Universitaire (CHU) Ambroise Pare
-
-
Antwerp
-
Edegem, Antwerp, Belgie, 2650
- Antwerp University Hospital
-
-
-
-
-
Barretos, Brazílie, SP 14784-400
- Fundacao Pio XII - Hospital de Cancer de Barretos - Hospital de Amor
-
Ijuí, Brazílie, 98700-00
- ONCOSITE - Centro de Pesquisa Clinica em Oncologia Ltda
-
Rio de Janeiro, Brazílie, 20231-050
- Instituto Nacional de Cancer - Ministrio da Sade
-
-
Paraná
-
Curitiba, Paraná, Brazílie, 82305-100
- Oncocentro-Centro de Oncologia do Parana
-
-
Porto Alegre
-
Porto Alegre, Porto Alegre, Brazílie, 90050-170
- Irmandade daSanta Casa de Misericordia de Porto Alegre
-
Porto Alegre, Porto Alegre, Brazílie, 90610-000
- Hospital Sao Lucas da PUCRS
-
Santa Cecília, Porto Alegre, Brazílie, RS 90035-903
- UPCO - Hospital de Clinicas de Porto Alegre
-
-
Salvador
-
Ondina, Salvador, Brazílie, BA 40170-110
- Nucleo de Oncologia da Bahia - NOB
-
-
-
-
-
Plovdiv, Bulharsko, 4000
- Complex Oncology Center - Plovdiv EOOD, First Department of Medical Oncology and Oncological Diseases in Gastroenterology
-
Sofia, Bulharsko, 1303
- Specialized hospital for active treatment of oncological diseases
-
Sofia, Bulharsko, 1632
- Multiprofile Hospital for Active Treatment Serdika EOOD Second Department of Medical Oncology
-
-
Panagyurishte
-
Panagyurishte, Panagyurishte, Bulharsko, 4500
- Multiprofile Hospital for Active Treatment - Uni Hospital OOD Department of Medical Oncology
-
-
-
-
-
Santiago, Chile
- Hospital Clinico Universidad de Chile
-
Santiago, Chile
- Clinica Alemana de Santiago
-
Santiago, Chile
- Centro de Estudios Clínicos SAGA
-
Santiago, Chile
- Clínica Santa María
-
Santiago, Chile
- Fundación Arturo López Pérez
-
-
Araucania
-
Temuco, Araucania, Chile, 4780000
- James Lind Centro de Investigación del Cáncer
-
-
Los Ríos Region
-
Valdivia, Los Ríos Region, Chile, 5090000
- Clinical Research Chile SpA
-
-
-
-
-
Aalborg, Dánsko, 9000
- Aalborg University Hospital
-
Næstved, Dánsko, 4700
- Sjællands Universitetshospital
-
Sønderborg, Dánsko, 6400
- Sønderborg Sygehus
-
Vejle, Dánsko, 7100
- Vejle Hospital
-
-
-
-
-
Besançon, Francie, 25030
- Hopital Jean Minjoz
-
Boulogne-Billancourt, Francie, 92100
- AssAP-HP - Hopital Ambroise-Pare
-
Brest, Francie, 29200
- Hopital Morvan CHU de Brest
-
Caen, Francie, 14000
- Centre François Baclesse
-
Caen, Francie, 14033
- CHU de Caen - Hopital Cote de Nacre
-
Créteil, Francie, 94000
- Centre Hospitalier Intercommunal de Creteil (CHIC)
-
Limoges, Francie, 87000
- Centre Hospitalier Universitaire CHU De Limoges
-
Nantes, Francie, Cedex 01 44093
- CHU de Nantes
-
Paris, Francie, 75018
- Bichat-Claude Bernard Hospital
-
Reims, Francie, 51092
- CHU Reims - Hpital Maison Blanche
-
Strasbourg, Francie, 67091
- Hopital Civil / Nouvel Hopital Civil
-
Suresnes, Francie, 92150
- Hospital Foch
-
Villejuif, Francie, 94805
- Gustave Roussy
-
-
-
-
-
Batumi, Gruzie, 6000
- High Technology Hospital Medcenter
-
Tbilisi, Gruzie, 112
- Todua Clinic
-
Tbilisi, Gruzie, 114
- New Hospitals
-
Tbilisi, Gruzie, 179
- JSC Evex Hospitals "Caraps Medline"
-
Tbilisi, Gruzie, 186
- LTD Cancer Research Centre
-
Tbilisi, Gruzie, 156
- Institute Of Clinical Oncology
-
-
-
-
-
Alessandria, Itálie, 15121
- A.O. SS. Antonio e Biagio e Cesare Arrigo di Alessandria
-
Ancona, Itálie, 60126
- Azienda Ospedaliero Universitaria delle Marche
-
Aviano, Itálie, 33081
- IRCCS Centro di Riferimento Oncologico
-
Bologna, Itálie, 40138
- IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola Malpighi Oncologia medica
-
Catania, Itálie, 95125
- Azienda Ospedaliera Univ. Policlinico G Rodolico San Marco
-
Cuneo, Itálie, 12100
- A.O. Santa Croce e Carle, Ospedale Carle
-
Florence, Itálie, 50134
- AOU Careggi
-
Genova, Itálie, 16149
- ASL 3 Genovese Oncologia Medica Villa Scassi
-
Milan, Itálie, 20089
- IRCCS Istituto Clinico Humanitas - Cancer Center
-
Naples, Itálie, 80138
- Universita degli Studi della Campania Luigi Vanvitelli
-
Novara, Itálie, 28100
- Ospedale Maggiore di Novara
-
Orbassano, Itálie, 10043
- Azienda Ospedaliero-Universitaria San Luigi Gonzaga
-
Padova, Itálie, 35128
- Oncologia Medica II Istituto Oncologico Veneto IRCCS
-
Piacenza, Itálie, 29121
- Azienda USL di Piacenza
-
Rionero in Vulture, Itálie, 85028
- Irccs-Crob
-
Roma, Itálie, 00128
- Fondazione Policlinico Universitario Campus Bio-Medico
-
Roma, Itálie, 00128
- IFO Regina Elena
-
Sondrio, Itálie, 23100
- ASST Valtellina e Alto Lario Ospedale di Sondrio
-
Varese, Itálie, 21100
- ASST Sette Laghi
-
-
-
-
-
Haifa, Izrael, 3109601
- Rambam Health Care Campu
-
Jerusalem, Izrael, 9103102
- Shaare Zedek Medical Center
-
Petah Tikva, Izrael, 49100
- Rabin Medical Center
-
Ramat Gan, Izrael
- The Chaim Sheba Medical Center
-
Tel Aviv, Izrael, 6423906
- Tel Aviv Sourasky Medical Center
-
-
-
-
Aomori
-
Hirosaki, Aomori, Japonsko, 036-8563
- Hirosaki University Hospital
-
-
Fukuoka
-
Fukuoka, Fukuoka, Japonsko, 812-8582
- Kyushu University Hospital
-
-
Hyōgo
-
Kobe, Hyōgo, Japonsko, 650-0047
- Kobe City Medical Center General Hospital
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, Japonsko, 920-8641
- Kanazawa University Hospital
-
-
Miyagi
-
Sendai, Miyagi, Japonsko, 980-0873
- Sendai Kousei Hospital
-
-
Okayama-ken
-
Kurashiki, Okayama-ken, Japonsko, 710-8602
- Ohara HealthCare Foundation Kurashiki Central Hospital
-
-
Osaka
-
Habikino, Osaka, Japonsko
- Osaka Habikino Medical Center
-
Hirakata-shi, Osaka, Japonsko, 573-1191
- Kansai Medical University Hospital
-
Izumi, Osaka, Japonsko, 594-0073
- Izumi City General Hospital
-
Izumi, Osaka, Japonsko, 594-0073
- Kanagawa Cancer Center
-
Kishiwada, Osaka, Japonsko, 596-8501
- Kishiwada City Hospital
-
-
Tokyo
-
Bunkyō-Ku, Tokyo, Japonsko
- Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
-
Koto-Ku, Tokyo, Japonsko, 135-8550
- The Cancer Institute Hospital Of JFCR
-
Shinjuku-Ku, Tokyo, Japonsko, 162-8655
- Center Hospital of the National Center for Global Health and Medicine
-
-
-
-
-
Cheongju-si, Jižní Korea, 28644
- Chungbuk National University Hospital
-
Gyeonggi-do, Jižní Korea, 13496
- CHA Bundang Medical Center, CHA University
-
Gyeonggi-do, Jižní Korea, 16247
- The Catholic University of Korea, St.Vincents Hospital
-
Incheon, Jižní Korea, 21565
- Gachon University Gil Medical Center
-
Incheon, Jižní Korea, 22332
- Inha University Hospital
-
Seoul, Jižní Korea, 05505
- Asan Medical Center
-
Seoul, Jižní Korea, 03181
- Kangbuk Samsung Hospital
-
Seoul, Jižní Korea, 06591
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
Seoul, Jižní Korea, 07061
- Seoul Metropolitan Government-Seoul National University Boramae Medical Center
-
-
-
-
-
Montreal, Kanada, H4A 3J1
- McGill University Health Centre (MUHC)
-
Toronto, Kanada, ON M5G 2C1
- University Health Network - Princess Margaret Hospital
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8V 5C2
- Hamilton Health Sciences -Juravinski Cancer Centre
-
Newmarket, Ontario, Kanada, L3Y 2P9
- Southlake Regional Health Centre
-
-
Quebec
-
Laval, Quebec, Kanada, H7M 3L9
- Hôpital de la Cité-de-la- Santé
-
Longueuil, Quebec, Kanada, J4V 2H1
- CISSS de la Montérégie-Centre - Hôpital Charles LeMoyne
-
-
-
-
-
Debrecen, Maďarsko, 4032
- Debreceni Egyetem - Klinikai Kozpont
-
Farkasgyepű, Maďarsko, 8582
- Veszprem Megyei Tudogyogyintezet Farkasgyepu
-
Kecskemét, Maďarsko, 6000
- Bacs-Kiskun County Hospital
-
Szolnok, Maďarsko, 5004
- Hetenyi G Korhaz, Onkologiai Kozpont
-
Törökbálint, Maďarsko, 2045
- Pulmonology Hospital Torokbalint
-
-
-
-
-
Bad Berka, Německo, 99437
- Zentralklinik Bad Berka GmbH
-
Berlin, Německo, 13125
- Evangelische Lungenklinik Berlin
-
Bremen, Německo, 28325
- Klinikum Bremen Ost
-
Duisburg, Německo, 74166
- Helios St. Johannes Klinikum
-
Esslingen am Neckar, Německo, 73730
- Klinikum Esslingen GmbH
-
Freiburg im Breisgau, Německo, 79106
- Universittsklinikum Freiburg
-
Gauting, Německo, 82131
- Asklepios Fachklinik München-Gauting
-
Halle, Německo, 06120
- Universitaetsklinikum Halle Saale
-
Halle, Německo, 06120
- Krankenhaus Martha-Maria Halle gGmbH
-
Heidelberg, Německo, 69126
- Thoraxclinic Heidelberg GmbH
-
Karlsruhe, Německo, 76137
- Vincentius-Diakonissen-Kliniken gAG Karlsruhe
-
Kassel, Německo, 34125
- Klinikum Kassel - Medizinische Klinik IV
-
Löwenstein, Německo, 74245
- Klinik Loewenstein gGmbH
-
Mannheim, Německo, 68167
- Universitaetsmedizin Mannheim
-
München, Německo, 81925
- Staedtisches Klinikum München - Bogenhausen
-
Offenbach, Německo, 63069
- Sana Klinikum Offenbach
-
-
Schleswig-Holstein
-
Großhansdorf, Schleswig-Holstein, Německo, 22927
- LungenClinic Grosshansdorf
-
-
-
-
-
Bialystok, Polsko, 15-569
- II Klinika Chorob Pluc i Gruzlicy
-
Gdynia, Polsko, 81-519
- Szpitale Pomorskie Sp. z o.o., Oddzial Onkologii K
-
Lodz, Polsko, 93-513
- Wojewódzkie Wielospecjalistyczne Centrum Onkologii
-
Lublin, Polsko, 20-093
- Specjalistyczna Praktyka Lekarska Slawomir Mandziuka
-
Prabuty, Polsko, 82-550
- Szpital Specjalistyczny w Prabutach Sp. z o.o
-
Rzeszów, Polsko, 35-021
- Mrukmed. Lekarz Beata Madej-Mruk i Partner. Sp.p
-
Tomaszów Mazowiecki, Polsko, 97-200
- Specjalistyczny Szpital Onkologiczny NU-MED sp. Z
-
-
-
-
-
Salzburg, Rakousko, A-5020
- University Hospital Salzburg
-
Vienna, Rakousko, A-1090
- Medizinische Universitaet Wien
-
-
-
-
-
Baia Mare, Rumunsko, 020945
- Sc Oncopremium Team Srl
-
Cluj-Napoca, Rumunsko, 400641
- Medisprof srl
-
Craiova, Rumunsko, 200385
- Oncolab SRL
-
Craiova, Rumunsko, 200746
- Centrul de Oncologie Sfantu Nectarie
-
Ovidiu, Rumunsko, 9005900
- Ovidius Clinical Hospital
-
Timișoara, Rumunsko, 300166
- Oncocenter Oncologie clinica S.R.L
-
-
-
-
-
Belfast, Spojené království, BT9 7AB
- Belfast Health and Social Care Trust
-
Harlow, Spojené království, CM20 1QX
- The Princess Alexandra Hospital
-
London, Spojené království, SE1 9RT
- Guys and St Thomas NHS Foundation Trust
-
Manchester, Spojené království, M20 4BX
- The Christie NHS Foundation Trust
-
Metropolitan Borough of Wirral, Spojené království, CH63 4JY
- Clatterbridge Hospital
-
Nottingham, Spojené království, NG5 1PB
- Nottingham University Hospitals NHS Trust
-
Wolverhampton, Spojené království, WV10 0QP
- The Royal Wolverhampton NHS Trust
-
-
-
-
Arizona
-
Chandler, Arizona, Spojené státy, 85224
- Ironwood Cancer & Research Centers
-
-
Arkansas
-
Hot Springs, Arkansas, Spojené státy, 71913
- Genesis Cancer and Blood
-
-
Florida
-
Fort Myers, Florida, Spojené státy, 33901
- Florida Cancer Specialists - South
-
St. Petersburg, Florida, Spojené státy, 33705
- Florida Cancer Specialists - North
-
Tallahassee, Florida, Spojené státy, 32308
- Florida Cancer Specialists - Panhandle
-
West Palm Beach, Florida, Spojené státy, 33401
- Florida Cancer Specialists - East
-
-
Illinois
-
Joliet, Illinois, Spojené státy, 60435
- Duly Health and Care
-
-
Kentucky
-
Louisville, Kentucky, Spojené státy, 40202
- Norton Cancer Institue, Downtown
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02215
- Dana-Farber Cancer Institute
-
-
Nebraska
-
Grand Island, Nebraska, Spojené státy, 68803
- Oncology Hematology West, PC (Grand Island)
-
Omaha, Nebraska, Spojené státy, 68130
- Oncology Hematology West, PC dba Nebraska Cancer Specialists
-
-
North Carolina
-
Pinehurst, North Carolina, Spojené státy, 28374
- FirstHealth Outpatient Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Spojené státy, 84106
- Utah Cancer Specialists
-
-
Washington
-
Tacoma, Washington, Spojené státy, 98405
- MultiCare Regional Cancer Center - Tacoma
-
-
Wisconsin
-
Milwaukee, Wisconsin, Spojené státy, 53226
- Froedtert Hospital/Medical College of Wisconsin
-
-
-
-
-
Taipei, Tchaj-wan, 106
- National Taiwan University Cancer Center
-
-
Chang Hua
-
Chang-hua, Chang Hua, Tchaj-wan, 500
- Changhua Christian Hospital
-
-
Chiayi
-
Dalin, Chiayi, Tchaj-wan, 622401
- Buddhist Dalin Tzu Chi Hospital
-
-
Kaohsiung
-
Kaohsiung City, Kaohsiung, Tchaj-wan, 83301
- Kaohsiung Chang Gung Memorial Hospital
-
-
-
-
Adana
-
Seyhan, Adana, Turecko (Türkiye), 01140
- Medicalpark Seyhan Hospital
-
-
Ankara
-
Çankaya, Ankara, Turecko (Türkiye), 06680
- Liv Hospital Ankara
-
-
Istanbul
-
Bağcılar, Istanbul, Turecko (Türkiye), 34214
- Bagcilar Medipol Mega University Hospital
-
Kadıköy, Istanbul, Turecko (Türkiye), 34722
- Goztepe Prof. Dr. Suleyman Yalcin City Hospital
-
-
Kocaeli
-
İzmit, Kocaeli, Turecko (Türkiye), 41380
- Kocaeli University Hospital
-
-
-
-
A Coruña
-
A Coruña, A Coruña, Španělsko, 15009
- Hospital Teresa Herrera C.H.U.A.
-
-
Barcelona
-
Badalona, Barcelona, Španělsko, 08916
- Institut Català d Oncologia (ICO) - Hospital Germans Trias i Pujol
-
Barcelona, Barcelona, Španělsko, 08035
- Hospital Universitari Vall d'Hebron
-
L'Hospitalet de Llobregat, Barcelona, Španělsko, 08908
- Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals
-
-
Cantabria
-
Santander, Cantabria, Španělsko, 39008
- Hospital Universitario Marqués de Valdecilla
-
-
Córdoba
-
Córdoba, Córdoba, Španělsko, 14004
- Hospital Universitario Reina Sofía
-
-
Gran Canaria
-
Las Palmas de Gran Canaria, Gran Canaria, Španělsko, 35016
- Complejo Hospitalario Materno-Insular de Gran Canaria
-
-
Lugo
-
Lugo, Lugo, Španělsko, 27003
- Hospital Universitario Lucus Augusti
-
-
Madrid
-
Madrid, Madrid, Španělsko, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Madrid, Španělsko, 28007
- Hospital General Universitario Gregorio Marañón
-
Madrid, Madrid, Španělsko, 28050
- Hospital Universitario HM Sanchinarro
-
Madrid, Madrid, Španělsko, 28006
- Hospital Universitario La Paz
-
Madrid, Madrid, Španělsko, 28033
- MD Anderson Cancer Center
-
Madrid, Madrid, Španělsko, 28027
- Clínica Universidad de Navarra
-
Madrid, Madrid, Španělsko, 28034
- Hospital Universitario Ramón y Cajal
-
Madrid, Madrid, Španělsko, 28040
- Hospital Clínico San Carlos
-
Madrid, Madrid, Španělsko, 28040
- Hospital Universitario Fundación Jimenez Díaz
-
-
Málaga
-
Málaga, Málaga, Španělsko, 29010
- Hospital Regional Universitario Málaga Hospital Civil
-
-
Navarre
-
Pamplona, Navarre, Španělsko, 31008
- Clínica Universidad de Navarra
-
-
Pontevedra
-
Vigo, Pontevedra, Španělsko, 36312
- Complexo Hospitalario Universitario De Vigo (CHUVI) - Hospital Xeral
-
-
Sevilla
-
Seville, Sevilla, Španělsko, 41013
- Hospital Universitario Virgen del Rocío
-
-
Valencia
-
Valencia, Valencia, Španělsko, 46026
- Hospital Universitari i Politècnic La Fe
-
-
Valladolid
-
Valladolid, Valladolid, Španělsko, 47003
- Hospital Clínico Universitario de Valladolid
-
-
Zaragoza
-
Zaragoza, Zaragoza, Španělsko, 50009
- Hospital Clínico Universitario Lozano Bleza
-
-
-
-
-
Basel, Švýcarsko, 4031
- University Hospital Basel
-
Bellinzona, Švýcarsko, 6500
- Istituto Oncologico della Svizzera Italiana
-
Frauenfeld, Švýcarsko, 8501
- Spital Thurgau - Kantonspital Frauenfeld
-
Lausanne, Švýcarsko, 1011
- Centre Hospitalier Universitaire Vaudois
-
Liestal, Švýcarsko, 4410
- Kantonsspital Baselland
-
Münsterlingen, Švýcarsko, 8596
- Spital Thurgau - Kantonsspital Muensterlingen
-
Villars-sur-Glâne, Švýcarsko, 1752
- HFR Freiburg Kantonsspital
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Voluntary written informed consent of the patient obtained before any study-specific procedure
-
Age≥18 years
-
Histologically or cytologically confirmed diagnosis of SCLC.
-
One prior line of platinum-containing chemotherapy with/without anti-PD-1 or anti-PD-L1 (Note: at least 70% of patients included in the study have to be pretreated with anti-PD-1 or anti-PD-L1)
-
Chemotherapy-free interval (CTFI, time from the last dose of first-line platinum-containing chemotherapy to the occurrence of progressive disease) ≥ 30 days (independent of the immunotherapy maintenance, if applicable)
-
Patients with history of Central Nervous System (CNS) metastases can participate provided they are pretreated and radiologically stable (i.e., without evidence of progression) for at least 4 weeks by repeated imaging (note: repeated imaging should be performed during study screening), asymptomatic, and without requirement of steroid treatment for at least 7 days before the first dose of study treatment
-
Eastern Cooperative Oncology Group (ECOG) PS ≤ 2
-
Adequate hematological, renal, metabolic and hepatic function:
- Hemoglobin ≥ 9.0 g/dL [patients may have received prior red blood cell (RBC) transfusion, if clinically indicated]; absolute neutrophil count (ANC) ≥ 2.0 x 10^9/L, and platelet count ≥ 100 x 10^9/L.
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 x upper limit of normal (ULN).
- Total bilirubin ≤ 1.5 x ULN or direct bilirubin ≤ ULN.
- Albumin ≥ 3.0 g/dL.
- Calculated creatinine clearance (CrCL) ≥ 30 mL/min (using Cockcroft and Gault's formula).
-
At least three weeks since last prior antineoplastic treatment and recovery to grade ≤ 1 from any adverse event (AE) related to previous anticancer treatment (excluding sensory neuropathy, immune-related hypothyroidism, anemia, asthenia and alopecia, all grade ≤ 2) according to the National Cancer InstituteCommon Terminology Criteria for Adverse Events (NCICTCAE) v.5.
-
Prior radiotherapy (RT): At least two weeks since completion of prophylactic cranial irradiation (PCI), and to any other site not previously specified.
-
Evidence of non-childbearing status for women of childbearing potential (WOCBP). WOCBP must agree to use a highly effective contraceptive measure up to seven months after treatment discontinuation. Fertile male patients with WOCBP partners should use condoms during treatment and for four months following the last investigational medicinal product (IMP) dose.
Exclusion Criteria:
-
Platinum-naïve patients or patients pretreated with more than one prior chemotherapy regimen (including patients re-challenged with same initial regimen).
-
Prior treatment with lurbinectedin, trabectedin, PM14, or topoisomerase I inhibitors (irinotecan, topotecan, etc.).
-
Active or untreated CNS metastases and/or carcinomatous meningitis.
-
Patients with limited-stage disease who are candidates for local or regional therapy, including PCI, thoracic RT or both, must have been offered that option and completed treatment or refused it prior to randomization.
-
Concomitant diseases/conditions:
- History or presence of unstable angina, myocardial infarction, congestive heart failure, or clinically significant valvular heart disease within last year.
- Symptomatic arrhythmia or any uncontrolled arrhythmia requiring ongoing treatment.
- Ongoing chronic alcohol consumption or cirrhosis with Child-Pugh score B or C.
- Known Gilbert's disease.
- Active uncontrolled infection. Serious non-healing wound, ulcer or bone fracture. Presence of external drainages.
- Ongoing, treatment-requiring, non-neoplastic chronic liver disease of any origin. For Hepatitis B, this includes positive tests for both Hepatitis B surface antigen (HBsAg) and quantitative Hepatitis B polymerase chain reaction (PCR). For Hepatitis C, this includes positive tests for both Hepatitis C antibody and quantitative Hepatitis C PCR. Subjects taking hepatitis related antiviral therapy within six months prior to the first dose of study drugs will also be excluded.
- Intermittent or continuous oxygen requirement within two weeks prior to randomization. Patients with confirmed or suspected diagnosis of diffuse interstitial lung disease or pulmonary fibrosis.
- Patients with a second invasive malignancy treated with chemotherapy and/or RT. Patients with a previous malignancy that was completely resected with curative intention three or more years prior to randomization, except treated in situ carcinoma of the cervix, basal or squamous cell skin carcinoma, and in situ transitional cell bladder carcinoma and who has been continuously in remission since then will be permitted.
- Limitation of the patient's ability to comply with the treatment or to follow the protocol.
- Documented or suspected invasive fungal infections requiring systemic treatment within 12 weeks of randomization.
- Known human immunodeficiency virus (HIV) infection.
- Any past or present chronic inflammatory colon and/or liver disease, past intestinal obstruction, pseudo or subocclusion or paralysis.
- Evident symptomatic pleural or cardiac effusion rapidly increasing and/or necessitating prompt local treatment within seven days.
- Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study (e.g.; COVID-19 disease).
-
RT in more than 35% of the bone marrow.
-
History of previous bone marrow and/or stem cell transplantation and allogenic transplant.
-
Patient has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of inactivated vaccines is allowed.
-
Impending need for RT (e.g., painful bone metastasis and/or risk of spinal cord compression).
-
History of allergy or hypersensitivity to any of the study drugs or any of their excipients.
-
Women who are pregnant or breast feeding and fertile patients (men and women) who are not able to use a highly effective method of contraception
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Lurbinectedin
Patients will consecutively receive lurbinectedin on Day 1 q3wk (every three weeks = one treatment cycle) |
Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 q3wk
Ostatní jména:
Lurbinectedin 2.0 mg/m² will be administered intravenously on Day 1 q3wk
Ostatní jména:
|
|
Experimentální: Lurbinectedin plus Irinotecan
Patients will consecutively receive the following q3wk (every three weeks = one treatment cycle):
|
Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 q3wk
Ostatní jména:
Lurbinectedin 2.0 mg/m² will be administered intravenously on Day 1 q3wk
Ostatní jména:
Irinotecan 75 mg/m² intravenously Days 1 & 8 q3wk For patients aged <70 years: irinotecan 350 mg/m² intravenously Day 1 q3wk For patients aged ≥70 years: irinotecan 300 mg/m² intravenously Day 1 q3wk |
|
Aktivní komparátor: Control arm
Best Investigator's choice prior to randomization between:
|
Irinotecan 75 mg/m² intravenously Days 1 & 8 q3wk For patients aged <70 years: irinotecan 350 mg/m² intravenously Day 1 q3wk For patients aged ≥70 years: irinotecan 300 mg/m² intravenously Day 1 q3wk Topotecan 2.3 mg/m² oral or 1.5 mg/m² intravenously Days 1-5 q3wk |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Overall survival
Časové okno: From the date of randomization to the date of death or last contact, up to 39 months
|
Overall survival (OS) will be calculated from the date of randomization to the date of death or last contact (in this case, survival will be censored on that date). |
From the date of randomization to the date of death or last contact, up to 39 months
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Progression-free survival by IRC (Independent Review Committee)
Časové okno: From the date of randomization to the date of progressive disease, death or last tumor assessment or further anticancer treatment, up to 39 months
|
Progression-free survival (PFS) will be calculated from the date of randomization to the date of documented progression per RECIST v.1.1 (Progressive disease is declared when there is an increase in sum of target disease ≥ 20%) or death (regardless of the cause of death). If the patient receives further antitumor therapy, withdraws from the study, or is lost to follow-up before progressive disease (PD), PFS will be censored at the date of last evaluable tumor assessment before the date of subsequent antitumor therapy. |
From the date of randomization to the date of progressive disease, death or last tumor assessment or further anticancer treatment, up to 39 months
|
|
Progression-free survival by IA (Investigator Assessment)
Časové okno: From the date of randomization to the date of progressive disease, death or last tumor assessment or further anticancer treatment, up to 39 months
|
Progression-free survival (PFS) will be calculated from the date of randomization to the date of documented progression per RECIST v.1.1 (Progressive disease is declared when there is an increase in sum of target disease ≥ 20%) or death (regardless of the cause of death). If the patient receives further antitumor therapy, withdraws from the study, or is lost to follow-up before progressive disease (PD), PFS will be censored at the date of last evaluable tumor assessment before the date of subsequent antitumor therapy. |
From the date of randomization to the date of progressive disease, death or last tumor assessment or further anticancer treatment, up to 39 months
|
|
Overall response rate by IRC
Časové okno: From the date of randomization to the date of death or last contact, up to 39 months
|
Overall response rate (ORR) will be the percentage of patients with complete or partial response as the best response obtained in any evaluation according to RECIST v.1.1. Progressive disease is declared when there is an increase in sum of target disease ≥ 20%, stable disease when the change is > -30% and ≤ 20%, partial response when there is a decrease in sum of target disease ≥ 30%, and complete response when all lesions have disappeared or all lesions have disappeared and all nodal disease is < 10 mm each. |
From the date of randomization to the date of death or last contact, up to 39 months
|
|
Overall response rate by IA
Časové okno: From the date of randomization to the date of death or last contact, up to 39 months
|
Overall response rate (ORR) will be the percentage of patients with complete or partial response as the best response obtained in any evaluation according to RECIST v.1.1. Progressive disease is declared when there is an increase in sum of target disease ≥ 20%, stable disease when the change is > -30% and ≤ 20%, partial response when there is a decrease in sum of target disease ≥ 30%, and complete response when all lesions have disappeared or all lesions have disappeared and all nodal disease is < 10 mm each. |
From the date of randomization to the date of death or last contact, up to 39 months
|
|
Overall survival rate at 12 months
Časové okno: At 12 months
|
Overall survival rate at 12 months is defined as the percentage of people who are still alive at 12 months after randomization. |
At 12 months
|
|
Overall survival rate at 24 months
Časové okno: At 24 months
|
Overall survival rate at 24 months is defined as the percentage of people who are still alive at 24 months after randomization. |
At 24 months
|
|
Progression-free survival rate at 6 months by IRC
Časové okno: At 6 months
|
Progression-free survival rate at 6 months is defined as the percentage of people who remain free from progression at 6 months after randomization |
At 6 months
|
|
Progression-free survival rate at 6 months by IA
Časové okno: At 6 months
|
Progression-free survival rate at 6 months is defined as the percentage of people who remain free from progression at 6 months after randomization |
At 6 months
|
|
Progression-free survival rate at 12 months by IRC
Časové okno: At 12 months
|
Progression-free survival rate at 12 months is defined as the percentage of people who remain free from progression at 12 months after randomization |
At 12 months
|
|
Progression-free survival rate at 12 months by IA
Časové okno: At 12 months
|
Progression-free survival rate at 12 months is defined as the percentage of people who remain free from progression at 12 months after randomization |
At 12 months
|
|
Duration of response by IRC
Časové okno: From the date of first documentation of complete or partial response to the date of documented progression disease, death or last contact, up to 39 months
|
Duration of response (DoR) will be calculated from the date of first documentation of response per RECIST v.1.1 (complete or partial response, whichever occurs first) to the date of documented PD or death. Progressive disease is declared when there is an increase in sum of target disease ≥ 20%, stable disease when the change is > -30% and ≤ 20%, partial response when there is a decrease in sum of target disease ≥ 30%, and complete response when all lesions have disappeared or all lesions have disappeared and all nodal disease is < 10 mm each. |
From the date of first documentation of complete or partial response to the date of documented progression disease, death or last contact, up to 39 months
|
|
Duration of response by IA
Časové okno: From the date of first documentation of complete or partial response to the date of documented progression disease, death or last contact, up to 39 months
|
Duration of response (DoR) will be calculated from the date of first documentation of response per RECIST v.1.1 (complete or partial response, whichever occurs first) to the date of documented PD or death. Progressive disease is declared when there is an increase in sum of target disease ≥ 20%, stable disease when the change is > -30% and ≤ 20%, partial response when there is a decrease in sum of target disease ≥ 30%, and complete response when all lesions have disappeared or all lesions have disappeared and all nodal disease is < 10 mm each. |
From the date of first documentation of complete or partial response to the date of documented progression disease, death or last contact, up to 39 months
|
|
Patient-reported outcomes
Časové okno: At baseline and every six weeks (± one week) until end of treatment, up to 39 months
|
To measure the quality of life of patients, the Lung Cancer Symptom Scale (LCSS) questionnaire will be analyzed. |
At baseline and every six weeks (± one week) until end of treatment, up to 39 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- PM1183-C-008-21
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .